NETRIS Pharma is developing a pipeline of drugs targeting different Dependence Receptors / Ligands.

By using several in vivo models of cancerogenesis in mice, NETRIS Pharma has shown that drug candidates targeting the various ligands of dependence receptors inhibit tumor growth and metastasis development.

These candidates are at various stages of development: from lead identification to clinical development.

NETRIS Pharma puts intellectual property at the center of its strategy.

The company holds worldwide exclusive rights and patents on major aspects of its activity and development.

Contact Us